Since 2007, MARS Bioimaging has been developing its spectral imaging technology based on the Medipix3 detector chip developed at CERN.
Researchers involved in this development come from a wide range of disciplines across a number of organisations, principally the University of Canterbury and the University of Otago.
To date, the Company has developed the world’s first preclinical spectral x-ray CT scanner and has sold several systems to leading researchers in New Zealand and overseas. These researchers are exploring the capabilities of the technology.
In September 2014, the Government announced that it would provide $12m of research funding over six years to the University of Canterbury and the University of Otago, Christchurch, to develop the world’s first human colour x-ray scanner.
Powerhouse has been an investor in MARS Bioimaging since 2013 and led a capital raising in 2014.
Powerhouse has assisted MARS Bioimaging with its research funding proposals.
Their 3D colour x-ray scanner could replace the millions of CT scans that carried out each year. Clinical trials with the scanner are starting early next year, with body part scanners for patients expected to be available in the coming years.
